Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3119-3126

  Smith, Mitchell R ^a   Li, Hailun ^b   Gordon, Leo ^c   Gascoyne, Randy D ^d   Paietta, Elisabeth ^e   Forero Torres, Andres ^f   Kahl, Brad S ^g   Advani, Ranjana ^h   Hong, Fangxin ^b   Horning, Sandra J ^h  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ALBERT EINSTEIN CANCER CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOTHESIS; HYPOXIA; INFECTION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUDY DESIGN; SYNCOPE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VINCRISTINE;

EID: 84865765565     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.2444     Document Type: Article

References (34)

1. Harris NL, Jaffé ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
2. Williams ME, Swerdlow SH: Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. Ann Oncol 5:71-73, 1994
3. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progressionfree survival. J Clin Oncol 20:1288-1294, 2002
4. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005
5. Romaguera JE, Fayad LE, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
6. Romaguera JE, Fayad LE, Feng L, et al: Tenyear follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200-208, 2010
7. Epner EM, Unger J, Miller T, et al: A multi-center trial of hyperCVAD + rituxan in patients with newly diagnosed mantle cell lymphoma. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2007 (abstr 387)
8. Merli F, Luminari S, Ilariucci F, et al: Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156:346-353, 2012
9. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
10. Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008
11. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCLnet). 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, December 4-7, 2010 (abstr A110)
12. Damon LE, Johnson JL, Niedzwiecki D, et al: Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27:6101-6108, 2009
13. Wang M, Oki Y, Pro B, et al: Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:5213-5218, 2009
14. Zelenetz AD, Noy A, Pandit-Taskar N, et al: Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 24:436s, 2006 (suppl; abstr 7560)
15. Grever MR, Lucas DM, Dewald GW, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799-804, 2007
16. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
17. [no authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
18. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
19. Herrmann A, Hoster E, Zwingers T, et al: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511-518, 2009
20. Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209-1213, 2009
21. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab is superior in respect of progression free survival and cr rate when compared with CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase iii study of the StiL (Study Group Indolent Lymphomas, Germany). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009 (abstr 405)
22. LaCasce AS, Vandergrift JL, Rodriguez MA, et al: Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database. Blood 119:2093-2099, 2012
23. Kluin-Nelemans JC, Hoster E, Walewski J, et al: R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: Outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Blood 118, 2011 (abstr 439)
24. Gopal AK, Press OW, Wilbur SM, et al: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112:830-835, 2008
25. Illidge TM, Bayne M, Brown NS, et al: Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113:1412-1421, 2009
26. Zinzani PL, Rossi G, Franceschetti S, et al: Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 16:3998-4004, 2010
27. Hainsworth JD, Spigel DR, Markus TM, et al: Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: A phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 9:223-228, 2009
28. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
29. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
30. Ghielmini M, Schmitz S-FH, Cogliatti S, et al: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705-711, 2005
31. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-4008, 2006
32. Kahl B, Longo WL, Eickhoff, JC, et al: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 17:1418-1423, 2006
33. Friedberg JW, Vose JM, Kelly JL, et al: The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117:2807-2812, 2011
34. Fowler N, Kahl BS, Lee P, et al: Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 29:3389-3395, 2011